Saturday 17 October 2026
Export SLS’s income statement to Excel — free account
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million. In the quarter to June 2026, EPS grew 28.6% and free cash flow fell 3.52%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
9.98
1.36
−11.99%
Follow SLS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
18.29 | 16.60 | 10.25 | 7.50 | |
Current Ratio |
18.83 | 17.22 | 10.72 | 8.28 | |
Net Debt/EBITDA |
13.03 | 11.59 | 8.71 | 6.27 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 1.05 | 0.64 | 1.04 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.02 | 0.02 | 0.04 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.04) | (0.05) | (0.05) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.05) | (0.05) | (0.07) | |
Cash per Share |
0.73 | 0.62 | 0.66 | 0.41 | |
Shareholders Equity per Share |
0.73 | 0.62 | 0.65 | 0.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.73 | 0.62 | 0.65 | 0.42 | |
Free Cash Flow |
(7.59) | (8.85) | (4.92) | (7.07) | |
Working Capital |
134.94 | 104.71 | 68.19 | 43.13 | |
Net Current Asset Value |
134.78 | 104.40 | 67.74 | 43.13 | |
| Other line items | |||||
Average Payables |
3.21 | 3.69 | 3.22 | 3.43 | |
Average Assets |
88.84 | 74.57 | 48.89 | 39.03 | |
Average Common Equity |
81.90 | 67.59 | 40.17 | 30.76 |
Columns are period end dates